SK129897A3 - Pyrrolidinyl hydroxamic acid derivatives, method and intermediate products for their production and pharmaceutical compositions process - Google Patents

Pyrrolidinyl hydroxamic acid derivatives, method and intermediate products for their production and pharmaceutical compositions process Download PDF

Info

Publication number: SK129897A3
Authority: SK; Slovakia
Prior art keywords: hydroxy; formula; acetamide; phenyl; phenylethyl
Prior art date: 1995-03-31

Application number

SK1298-97A

Other languages

English (en)

Slovak (sk)

Inventor

Fumitaka Ito

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-03-31

Filing date

1996-03-28

Publication date

1998-11-04

1996-03-28 Application filed by Pfizer filed Critical Pfizer

1998-11-04 Publication of SK129897A3 publication Critical patent/SK129897A3/sk

Links

238000000034 method Methods 0.000 title claims abstract description 102
-1 Pyrrolidinyl hydroxamic Chemical compound 0.000 title claims abstract description 75
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 8
239000002253 acid Substances 0.000 title claims description 18
238000004519 manufacturing process Methods 0.000 title description 2
239000013067 intermediate product Substances 0.000 title 1
150000001875 compounds Chemical class 0.000 claims abstract description 150
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 92
239000001257 hydrogen Substances 0.000 claims abstract description 72
125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 40
125000006239 protecting group Chemical group 0.000 claims abstract description 22
150000003839 salts Chemical class 0.000 claims abstract description 18
125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract description 17
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 15
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims abstract description 11
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 11
239000000730 antalgic agent Substances 0.000 claims abstract description 9
125000001424 substituent group Chemical group 0.000 claims abstract description 9
125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims abstract description 8
239000003795 chemical substances by application Substances 0.000 claims abstract description 7
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 7
208000004998 Abdominal Pain Diseases 0.000 claims abstract description 6
230000003444 anaesthetic effect Effects 0.000 claims abstract description 6
239000002260 anti-inflammatory agent Substances 0.000 claims abstract description 6
230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 6
239000002934 diuretic Substances 0.000 claims abstract description 6
230000001882 diuretic effect Effects 0.000 claims abstract description 6
239000003193 general anesthetic agent Substances 0.000 claims abstract description 6
239000004090 neuroprotective agent Substances 0.000 claims abstract description 6
230000000202 analgesic effect Effects 0.000 claims abstract description 5
125000001544 thienyl group Chemical group 0.000 claims abstract description 4
125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims abstract description 3
125000002541 furyl group Chemical group 0.000 claims abstract description 3
125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims abstract description 3
125000001624 naphthyl group Chemical group 0.000 claims abstract description 3
125000004076 pyridyl group Chemical group 0.000 claims abstract description 3
239000000203 mixture Substances 0.000 claims description 45
125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims description 30
DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 12
125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 11
230000000694 effects Effects 0.000 claims description 11
241000124008 Mammalia Species 0.000 claims description 9
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 9
238000002360 preparation method Methods 0.000 claims description 9
125000000217 alkyl group Chemical group 0.000 claims description 7
229910052736 halogen Inorganic materials 0.000 claims description 7
150000002367 halogens Chemical group 0.000 claims description 7
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 5
AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims description 5
208000035475 disorder Diseases 0.000 claims description 5
QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 claims description 5
125000004201 2,4-dichlorophenyl group Chemical group [H]C1=C([H])C(*)=C(Cl)C([H])=C1Cl 0.000 claims description 4
HOGIAGOSNJXVGR-LJQANCHMSA-N 2-(3,4-dichlorophenyl)-n-hydroxy-n-[(1s)-1-phenyl-2-pyrrolidin-1-ylethyl]acetamide Chemical compound C([C@@H](N(O)C(=O)CC=1C=C(Cl)C(Cl)=CC=1)C=1C=CC=CC=1)N1CCCC1 HOGIAGOSNJXVGR-LJQANCHMSA-N 0.000 claims description 4
125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims description 4
239000012359 Methanesulfonyl chloride Substances 0.000 claims description 4
125000004432 carbon atom Chemical group C* 0.000 claims description 4
125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 4
125000005083 alkoxyalkoxy group Chemical group 0.000 claims description 3
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims description 3
125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 2
150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 2
239000003814 drug Substances 0.000 claims description 2
125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 2
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
229940121954 Opioid receptor agonist Drugs 0.000 claims 1
DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical group C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 claims 1
USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical class C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 claims 1
239000003402 opiate agonist Substances 0.000 claims 1
NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical class C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 abstract description 5
241000282414 Homo sapiens Species 0.000 abstract description 4
201000010099 disease Diseases 0.000 abstract description 2
125000003545 alkoxy group Chemical group 0.000 abstract 2
ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical group C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 abstract 2
125000001475 halogen functional group Chemical group 0.000 abstract 2
JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 abstract 1
125000005530 alkylenedioxy group Chemical group 0.000 abstract 1
125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 abstract 1
239000004305 biphenyl Chemical group 0.000 abstract 1
235000010290 biphenyl Nutrition 0.000 abstract 1
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 99
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 75
238000005481 NMR spectroscopy Methods 0.000 description 74
150000002431 hydrogen Chemical group 0.000 description 57
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 46
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 44
238000004458 analytical method Methods 0.000 description 43
239000003921 oil Substances 0.000 description 38
235000019198 oils Nutrition 0.000 description 38
239000007787 solid Substances 0.000 description 32
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 30
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 30
239000000243 solution Substances 0.000 description 26
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 22
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 22
229910052938 sodium sulfate Inorganic materials 0.000 description 22
235000011152 sodium sulphate Nutrition 0.000 description 22
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 20
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 20
229910000041 hydrogen chloride Inorganic materials 0.000 description 20
JVWZVGMSJISZQR-PYNWJHIZSA-N (2r)-2-[(3s)-3-(oxan-2-yloxy)pyrrolidin-1-yl]-2-phenylethanol Chemical compound O([C@H]1CCN(C1)[C@@H](CO)C=1C=CC=CC=1)C1CCCCO1 JVWZVGMSJISZQR-PYNWJHIZSA-N 0.000 description 19
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 18
150000001412 amines Chemical class 0.000 description 17
230000008018 melting Effects 0.000 description 16
238000002844 melting Methods 0.000 description 16
239000002904 solvent Substances 0.000 description 16
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
238000006243 chemical reaction Methods 0.000 description 15
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
239000000126 substance Substances 0.000 description 14
239000000047 product Substances 0.000 description 13
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 12
239000012267 brine Substances 0.000 description 12
239000011541 reaction mixture Substances 0.000 description 12
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 12
CNONYXFNOHXTLC-KBPBESRZSA-N (2r)-2-[(3s)-3-(methoxymethoxy)pyrrolidin-1-yl]-2-phenylethanol Chemical compound C1[C@@H](OCOC)CCN1[C@@H](CO)C1=CC=CC=C1 CNONYXFNOHXTLC-KBPBESRZSA-N 0.000 description 11
239000000284 extract Substances 0.000 description 11
238000001914 filtration Methods 0.000 description 11
229920006395 saturated elastomer Polymers 0.000 description 11
238000004440 column chromatography Methods 0.000 description 10
239000000741 silica gel Substances 0.000 description 10
229910002027 silica gel Inorganic materials 0.000 description 10
235000017557 sodium bicarbonate Nutrition 0.000 description 10
229910000030 sodium bicarbonate Inorganic materials 0.000 description 10
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
239000000556 agonist Substances 0.000 description 8
239000000843 powder Substances 0.000 description 8
239000000543 intermediate Substances 0.000 description 7
YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 6
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
241000700159 Rattus Species 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
238000010992 reflux Methods 0.000 description 6
MWGPNRQVCPJJBW-LURJTMIESA-N (3s)-3-(methoxymethoxy)pyrrolidine Chemical compound COCO[C@H]1CCNC1 MWGPNRQVCPJJBW-LURJTMIESA-N 0.000 description 5
ZOUPGSMSNQLUNW-UHFFFAOYSA-N 2-(3,4-dichlorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=C(Cl)C(Cl)=C1 ZOUPGSMSNQLUNW-UHFFFAOYSA-N 0.000 description 5
FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 5
125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 5
241000282412 Homo Species 0.000 description 5
239000007864 aqueous solution Substances 0.000 description 5
239000000706 filtrate Substances 0.000 description 5
239000002632 kappa opiate receptor agonist Substances 0.000 description 5
125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 5
238000010561 standard procedure Methods 0.000 description 5
238000012360 testing method Methods 0.000 description 5
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 5
JCZDMBKPCOKANB-VEDVMXKPSA-N (3r)-3-(oxan-2-yloxy)pyrrolidine Chemical compound C1NCC[C@H]1OC1OCCCC1 JCZDMBKPCOKANB-VEDVMXKPSA-N 0.000 description 4
206010010904 Convulsion Diseases 0.000 description 4
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
239000012230 colorless oil Substances 0.000 description 4
239000013078 crystal Substances 0.000 description 4
239000003085 diluting agent Substances 0.000 description 4
238000001704 evaporation Methods 0.000 description 4
230000008020 evaporation Effects 0.000 description 4
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 4
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
238000000746 purification Methods 0.000 description 4
238000003756 stirring Methods 0.000 description 4
DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 4
125000004199 4-trifluoromethylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C(F)(F)F 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 3
UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
102000003840 Opioid Receptors Human genes 0.000 description 3
108090000137 Opioid Receptors Proteins 0.000 description 3
238000005917 acylation reaction Methods 0.000 description 3
230000029936 alkylation Effects 0.000 description 3
238000005804 alkylation reaction Methods 0.000 description 3
235000011114 ammonium hydroxide Nutrition 0.000 description 3
229940035676 analgesics Drugs 0.000 description 3
238000003556 assay Methods 0.000 description 3
229910052799 carbon Inorganic materials 0.000 description 3
239000003054 catalyst Substances 0.000 description 3
239000007789 gas Substances 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
SHFJWMWCIHQNCP-UHFFFAOYSA-M hydron;tetrabutylazanium;sulfate Chemical compound OS([O-])(=O)=O.CCCC[N+](CCCC)(CCCC)CCCC SHFJWMWCIHQNCP-UHFFFAOYSA-M 0.000 description 3
239000002674 ointment Substances 0.000 description 3
230000003287 optical effect Effects 0.000 description 3
239000003960 organic solvent Substances 0.000 description 3
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
229940044601 receptor agonist Drugs 0.000 description 3
239000000018 receptor agonist Substances 0.000 description 3
238000010898 silica gel chromatography Methods 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
125000001412 tetrahydropyranyl group Chemical group 0.000 description 3
WPVZJYFBUIBTRC-SECBINFHSA-N (1s)-1-(3-methylphenyl)ethane-1,2-diol Chemical compound CC1=CC=CC([C@H](O)CO)=C1 WPVZJYFBUIBTRC-SECBINFHSA-N 0.000 description 2
CYRLHHDBZGNKEA-SNVBAGLBSA-N (1s)-1-[3-(methoxymethoxy)phenyl]ethane-1,2-diol Chemical compound COCOC1=CC=CC([C@H](O)CO)=C1 CYRLHHDBZGNKEA-SNVBAGLBSA-N 0.000 description 2
UZCBDOLPPICICR-YNPPLXCJSA-N (1s)-2-[(3r)-3-(oxan-2-yloxy)pyrrolidin-1-yl]-1-phenylethanol Chemical compound O([C@@H]1CCN(C1)C[C@@H](O)C=1C=CC=CC=1)C1CCCCO1 UZCBDOLPPICICR-YNPPLXCJSA-N 0.000 description 2
RCPWHIUMQKNAHD-LSDHHAIUSA-N (1s)-2-[(3s)-3-(methoxymethoxy)pyrrolidin-1-yl]-1-(3-methylphenyl)ethanol Chemical compound C1[C@@H](OCOC)CCN1C[C@@H](O)C1=CC=CC(C)=C1 RCPWHIUMQKNAHD-LSDHHAIUSA-N 0.000 description 2
CDLHNMKWIQZIOI-LSDHHAIUSA-N (1s)-2-[(3s)-3-(methoxymethoxy)pyrrolidin-1-yl]-1-(4-methylphenyl)ethanol Chemical compound C1[C@@H](OCOC)CCN1C[C@@H](O)C1=CC=C(C)C=C1 CDLHNMKWIQZIOI-LSDHHAIUSA-N 0.000 description 2
JHAQDLQRDPXVQL-GJZGRUSLSA-N (2r)-2-[(3s)-3-(methoxymethoxy)pyrrolidin-1-yl]-2-(4-methylphenyl)ethanol Chemical compound C1[C@@H](OCOC)CCN1[C@@H](CO)C1=CC=C(C)C=C1 JHAQDLQRDPXVQL-GJZGRUSLSA-N 0.000 description 2
QAWJAMQTRGCJMH-SECBINFHSA-N (2s)-2-(4-methylphenyl)oxirane Chemical compound C1=CC(C)=CC=C1[C@@H]1OC1 QAWJAMQTRGCJMH-SECBINFHSA-N 0.000 description 2
GLZXZTWPGUEGPE-AAFJCEBUSA-N (3r)-1-benzyl-3-(oxan-2-yloxy)pyrrolidine Chemical compound O([C@@H]1CCN(C1)CC=1C=CC=CC=1)C1CCCCO1 GLZXZTWPGUEGPE-AAFJCEBUSA-N 0.000 description 2
HPZJMUBDEAMBFI-WTNAPCKOSA-N (D-Ala(2)-mephe(4)-gly-ol(5))enkephalin Chemical compound C([C@H](N)C(=O)N[C@H](C)C(=O)NCC(=O)N(C)[C@@H](CC=1C=CC=CC=1)C(=O)NCCO)C1=CC=C(O)C=C1 HPZJMUBDEAMBFI-WTNAPCKOSA-N 0.000 description 2
IJXJGQCXFSSHNL-QMMMGPOBSA-N (R)-(-)-2-Phenylglycinol Chemical compound OC[C@H](N)C1=CC=CC=C1 IJXJGQCXFSSHNL-QMMMGPOBSA-N 0.000 description 2
AWMVMTVKBNGEAK-QMMMGPOBSA-N (R)-styrene oxide Chemical compound C1O[C@@H]1C1=CC=CC=C1 AWMVMTVKBNGEAK-QMMMGPOBSA-N 0.000 description 2
LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 2
MBKVNMMQARELRC-PBGWYDOXSA-N 2-(3,4-dichlorophenyl)-n-(oxan-2-yloxy)-n-[(1s)-2-[(3s)-3-(oxan-2-yloxy)pyrrolidin-1-yl]-1-phenylethyl]acetamide Chemical compound C1=C(Cl)C(Cl)=CC=C1CC(=O)N([C@H](CN1C[C@H](CC1)OC1OCCCC1)C=1C=CC=CC=1)OC1OCCCC1 MBKVNMMQARELRC-PBGWYDOXSA-N 0.000 description 2
IXGFNBMRTNSCMU-YRVHRZEMSA-N 2-(3,4-dichlorophenyl)-n-[(1s)-2-[(3s)-3-(methoxymethoxy)pyrrolidin-1-yl]-1-(3-methylphenyl)ethyl]-n-(oxan-2-yloxy)acetamide Chemical compound C1[C@@H](OCOC)CCN1C[C@H](C=1C=C(C)C=CC=1)N(C(=O)CC=1C=C(Cl)C(Cl)=CC=1)OC1OCCCC1 IXGFNBMRTNSCMU-YRVHRZEMSA-N 0.000 description 2
UCBXSHMDLGBSTO-AREMUKBSSA-N 2-(3,4-dichlorophenyl)-n-phenylmethoxy-n-[(1s)-1-phenyl-2-pyrrolidin-1-ylethyl]acetamide Chemical compound C1=C(Cl)C(Cl)=CC=C1CC(=O)N([C@H](CN1CCCC1)C=1C=CC=CC=1)OCC1=CC=CC=C1 UCBXSHMDLGBSTO-AREMUKBSSA-N 0.000 description 2
YCAKYFIYUHHCKW-UHFFFAOYSA-N 2-(3,4-difluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=C(F)C(F)=C1 YCAKYFIYUHHCKW-UHFFFAOYSA-N 0.000 description 2
GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 2
125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 2
125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 2
125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 description 2
125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 description 2
125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 2
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 2
108700022183 Ala(2)-MePhe(4)-Gly(5)- Enkephalin Proteins 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
101150065749 Churc1 gene Proteins 0.000 description 2
108700022182 D-Penicillamine (2,5)- Enkephalin Proteins 0.000 description 2
MCMMCRYPQBNCPH-WMIMKTLMSA-N DPDPE Chemical compound C([C@H](N)C(=O)N[C@@H]1C(C)(C)SSC([C@@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)CNC1=O)C(O)=O)(C)C)C1=CC=C(O)C=C1 MCMMCRYPQBNCPH-WMIMKTLMSA-N 0.000 description 2
BUDQDWGNQVEFAC-UHFFFAOYSA-N Dihydropyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
QMXOFBXZEKTJIK-UHFFFAOYSA-N Glycinol Natural products C1=C(O)C=C2OCC3(O)C4=CC=C(O)C=C4OC3C2=C1 QMXOFBXZEKTJIK-UHFFFAOYSA-N 0.000 description 2
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
102100038239 Protein Churchill Human genes 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
AWMVMTVKBNGEAK-UHFFFAOYSA-N Styrene oxide Chemical class C1OC1C1=CC=CC=C1 AWMVMTVKBNGEAK-UHFFFAOYSA-N 0.000 description 2
DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
GNEUNRFKCMUKPB-MRXNPFEDSA-N [(2s)-2-hydroxy-2-(3-methylphenyl)ethyl] 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OC[C@@H](O)C1=CC=CC(C)=C1 GNEUNRFKCMUKPB-MRXNPFEDSA-N 0.000 description 2
ULEKQBRCHWEQHX-MRXNPFEDSA-N [(2s)-2-hydroxy-2-(4-methylphenyl)ethyl] 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1[C@H](O)COS(=O)(=O)C1=CC=C(C)C=C1 ULEKQBRCHWEQHX-MRXNPFEDSA-N 0.000 description 2
GQTZSUDZKNVOFX-QGZVFWFLSA-N [(2s)-2-hydroxy-2-[3-(methoxymethoxy)phenyl]ethyl] 4-methylbenzenesulfonate Chemical compound COCOC1=CC=CC([C@H](O)COS(=O)(=O)C=2C=CC(C)=CC=2)=C1 GQTZSUDZKNVOFX-QGZVFWFLSA-N 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
230000010933 acylation Effects 0.000 description 2
230000008484 agonism Effects 0.000 description 2
239000000908 ammonium hydroxide Substances 0.000 description 2
239000007900 aqueous suspension Substances 0.000 description 2
239000012298 atmosphere Substances 0.000 description 2
150000007514 bases Chemical class 0.000 description 2
239000000969 carrier Substances 0.000 description 2
239000003086 colorant Substances 0.000 description 2
239000006071 cream Substances 0.000 description 2
PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
206010013663 drug dependence Diseases 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
239000000945 filler Substances 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
235000013355 food flavoring agent Nutrition 0.000 description 2
235000003599 food sweetener Nutrition 0.000 description 2
239000000499 gel Substances 0.000 description 2
WUAXWQRULBZETB-UHFFFAOYSA-N homoveratric acid Chemical compound COC1=CC=C(CC(O)=O)C=C1OC WUAXWQRULBZETB-UHFFFAOYSA-N 0.000 description 2
235000015110 jellies Nutrition 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
229920000609 methyl cellulose Polymers 0.000 description 2
239000001923 methylcellulose Substances 0.000 description 2
125000000896 monocarboxylic acid group Chemical group 0.000 description 2
229960005181 morphine Drugs 0.000 description 2
102000051367 mu Opioid Receptors Human genes 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
NLXXVSKHVGDQAT-UHFFFAOYSA-N o-(oxan-2-yl)hydroxylamine Chemical compound NOC1CCCCO1 NLXXVSKHVGDQAT-UHFFFAOYSA-N 0.000 description 2
229940127240 opiate Drugs 0.000 description 2
NXJCBFBQEVOTOW-UHFFFAOYSA-L palladium(2+);dihydroxide Chemical compound O[Pd]O NXJCBFBQEVOTOW-UHFFFAOYSA-L 0.000 description 2
239000006072 paste Substances 0.000 description 2
229910000027 potassium carbonate Inorganic materials 0.000 description 2
230000001624 sedative effect Effects 0.000 description 2
GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
239000008247 solid mixture Substances 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
208000011117 substance-related disease Diseases 0.000 description 2
239000000725 suspension Substances 0.000 description 2
239000003765 sweetening agent Substances 0.000 description 2
239000003826 tablet Substances 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
108020001612 μ-opioid receptors Proteins 0.000 description 2
CUAZMIQRVQSLKX-LJQANCHMSA-N (1s)-1-phenyl-n-phenylmethoxy-2-pyrrolidin-1-ylethanamine Chemical compound C([C@@H](NOCC=1C=CC=CC=1)C=1C=CC=CC=1)N1CCCC1 CUAZMIQRVQSLKX-LJQANCHMSA-N 0.000 description 1
PSZIWKRIFPTGTA-QINBWVTOSA-N (1s)-n-(oxan-2-yloxy)-2-[(3s)-3-(oxan-2-yloxy)pyrrolidin-1-yl]-1-phenylethanamine Chemical compound N([C@H](CN1C[C@H](CC1)OC1OCCCC1)C=1C=CC=CC=1)OC1CCCCO1 PSZIWKRIFPTGTA-QINBWVTOSA-N 0.000 description 1
IWWIUDASVBIUQU-PYNWJHIZSA-N (2r)-2-(4-fluorophenyl)-2-[(3s)-3-(oxan-2-yloxy)pyrrolidin-1-yl]ethanol Chemical compound O([C@H]1CCN(C1)[C@@H](CO)C=1C=CC(F)=CC=1)C1CCCCO1 IWWIUDASVBIUQU-PYNWJHIZSA-N 0.000 description 1
JVWZVGMSJISZQR-GARXDOFDSA-N (2r)-2-[(3r)-3-(oxan-2-yloxy)pyrrolidin-1-yl]-2-phenylethanol Chemical compound O([C@@H]1CCN(C1)[C@@H](CO)C=1C=CC=CC=1)C1CCCCO1 JVWZVGMSJISZQR-GARXDOFDSA-N 0.000 description 1
RTZBSBZVOWQBQX-GJZGRUSLSA-N (2r)-2-[(3s)-3-(methoxymethoxy)pyrrolidin-1-yl]-2-(3-methylphenyl)ethanol Chemical compound C1[C@@H](OCOC)CCN1[C@@H](CO)C1=CC=CC(C)=C1 RTZBSBZVOWQBQX-GJZGRUSLSA-N 0.000 description 1
YQDISZZVFYLYOG-LBPRGKRZSA-N (2r)-2-phenyl-2-pyrrolidin-1-ylethanol Chemical compound N1([C@@H](CO)C=2C=CC=CC=2)CCCC1 YQDISZZVFYLYOG-LBPRGKRZSA-N 0.000 description 1
CNONYXFNOHXTLC-UONOGXRCSA-N (2s)-2-[(3s)-3-(methoxymethoxy)pyrrolidin-1-yl]-2-phenylethanol Chemical compound C1[C@@H](OCOC)CCN1[C@H](CO)C1=CC=CC=C1 CNONYXFNOHXTLC-UONOGXRCSA-N 0.000 description 1
YQMXOIAIYXXXEE-LLVKDONJSA-N (3r)-1-benzylpyrrolidin-3-ol Chemical compound C1[C@H](O)CCN1CC1=CC=CC=C1 YQMXOIAIYXXXEE-LLVKDONJSA-N 0.000 description 1
JCZDMBKPCOKANB-IENPIDJESA-N (3s)-3-(oxan-2-yloxy)pyrrolidine Chemical compound C1NCC[C@@H]1OC1OCCCC1 JCZDMBKPCOKANB-IENPIDJESA-N 0.000 description 1
YBADLXQNJCMBKR-UHFFFAOYSA-N (4-nitrophenyl)acetic acid Chemical compound OC(=O)CC1=CC=C([N+]([O-])=O)C=C1 YBADLXQNJCMBKR-UHFFFAOYSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
ZWXDAANEJMSCEX-UHFFFAOYSA-N 1-(3-anilinophenyl)ethanone Chemical compound CC(=O)C1=CC=CC(NC=2C=CC=CC=2)=C1 ZWXDAANEJMSCEX-UHFFFAOYSA-N 0.000 description 1
KTZVZZJJVJQZHV-UHFFFAOYSA-N 1-chloro-4-ethenylbenzene Chemical compound ClC1=CC=C(C=C)C=C1 KTZVZZJJVJQZHV-UHFFFAOYSA-N 0.000 description 1
YYRGFWRHEKGYOX-UHFFFAOYSA-N 1-ethenyl-3-(methoxymethoxy)benzene Chemical compound COCOC1=CC=CC(C=C)=C1 YYRGFWRHEKGYOX-UHFFFAOYSA-N 0.000 description 1
JZHGRUMIRATHIU-UHFFFAOYSA-N 1-ethenyl-3-methylbenzene Chemical compound CC1=CC=CC(C=C)=C1 JZHGRUMIRATHIU-UHFFFAOYSA-N 0.000 description 1
CEWDRCQPGANDRS-UHFFFAOYSA-N 1-ethenyl-4-(trifluoromethyl)benzene Chemical compound FC(F)(F)C1=CC=C(C=C)C=C1 CEWDRCQPGANDRS-UHFFFAOYSA-N 0.000 description 1
UAJRSHJHFRVGMG-UHFFFAOYSA-N 1-ethenyl-4-methoxybenzene Chemical compound COC1=CC=C(C=C)C=C1 UAJRSHJHFRVGMG-UHFFFAOYSA-N 0.000 description 1
ODVLMCWNGKLROU-UHFFFAOYSA-N 2-(1,3-benzodioxol-5-yl)acetic acid Chemical compound OC(=O)CC1=CC=C2OCOC2=C1 ODVLMCWNGKLROU-UHFFFAOYSA-N 0.000 description 1
IFOMXIGWQFOYLA-UHFFFAOYSA-N 2-(1-benzothiophen-4-yl)acetic acid Chemical compound OC(=O)CC1=CC=CC2=C1C=CS2 IFOMXIGWQFOYLA-UHFFFAOYSA-N 0.000 description 1
RSAGOGCETZHNDA-UHFFFAOYSA-N 2-(2,3,5-trichlorophenyl)acetic acid Chemical compound OC(=O)CC1=CC(Cl)=CC(Cl)=C1Cl RSAGOGCETZHNDA-UHFFFAOYSA-N 0.000 description 1
YWMXEUIQZOQESD-UHFFFAOYSA-N 2-(2,3-dichlorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Cl)=C1Cl YWMXEUIQZOQESD-UHFFFAOYSA-N 0.000 description 1
XOVZSZLZMZBHHV-UHFFFAOYSA-N 2-(2,4,6-trichlorophenyl)acetic acid Chemical compound OC(=O)CC1=C(Cl)C=C(Cl)C=C1Cl XOVZSZLZMZBHHV-UHFFFAOYSA-N 0.000 description 1
CQWMQAKKAHTCSC-UHFFFAOYSA-N 2-(2,4,6-trimethylphenyl)acetic acid Chemical compound CC1=CC(C)=C(CC(O)=O)C(C)=C1 CQWMQAKKAHTCSC-UHFFFAOYSA-N 0.000 description 1
BLYSUNLCJIFEGY-UHFFFAOYSA-N 2-(2,4-dichlorophenyl)-2-phenylacetic acid Chemical compound OC(=O)C(c1ccccc1)c1ccc(Cl)cc1Cl BLYSUNLCJIFEGY-UHFFFAOYSA-N 0.000 description 1
GWTUGCOXTFFBMM-UHFFFAOYSA-N 2-(2,5-dichlorophenyl)acetic acid Chemical compound OC(=O)CC1=CC(Cl)=CC=C1Cl GWTUGCOXTFFBMM-UHFFFAOYSA-N 0.000 description 1
SFAILOOQFZNOAU-UHFFFAOYSA-N 2-(2,6-dichlorophenyl)acetic acid Chemical compound OC(=O)CC1=C(Cl)C=CC=C1Cl SFAILOOQFZNOAU-UHFFFAOYSA-N 0.000 description 1
MVVCJIVSQDJOOR-VKLKMBQZSA-N 2-(2-aminophenyl)-n-[(1s)-2-[(3s)-3-hydroxypyrrolidin-1-yl]-1-phenylethyl]-n-methylacetamide;hydrochloride Chemical compound Cl.C([C@@H](N(C)C(=O)CC=1C(=CC=CC=1)N)C=1C=CC=CC=1)N1CC[C@H](O)C1 MVVCJIVSQDJOOR-VKLKMBQZSA-N 0.000 description 1
IUJAAIZKRJJZGQ-UHFFFAOYSA-N 2-(2-chlorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC=C1Cl IUJAAIZKRJJZGQ-UHFFFAOYSA-N 0.000 description 1
MBKVNMMQARELRC-IVIAQFCDSA-N 2-(3,4-dichlorophenyl)-n-(oxan-2-yloxy)-n-[(1s)-2-[(3r)-3-(oxan-2-yloxy)pyrrolidin-1-yl]-1-phenylethyl]acetamide Chemical compound C1=C(Cl)C(Cl)=CC=C1CC(=O)N([C@H](CN1C[C@@H](CC1)OC1OCCCC1)C=1C=CC=CC=1)OC1OCCCC1 MBKVNMMQARELRC-IVIAQFCDSA-N 0.000 description 1
VKYFYAIEINGWKF-NKJJMXICSA-N 2-(3,4-dichlorophenyl)-n-[(1s)-1-[3-(methoxymethoxy)phenyl]-2-[(3s)-3-(oxan-2-yloxy)pyrrolidin-1-yl]ethyl]-n-(oxan-2-yloxy)acetamide Chemical compound COCOC1=CC=CC([C@@H](CN2C[C@H](CC2)OC2OCCCC2)N(OC2OCCCC2)C(=O)CC=2C=C(Cl)C(Cl)=CC=2)=C1 VKYFYAIEINGWKF-NKJJMXICSA-N 0.000 description 1
OTTPBKINJOYJGW-UHFFFAOYSA-N 2-(3,4-dimethylphenyl)acetic acid Chemical compound CC1=CC=C(CC(O)=O)C=C1C OTTPBKINJOYJGW-UHFFFAOYSA-N 0.000 description 1
RERINLRFXYGZEE-UHFFFAOYSA-N 2-(3,5-dichlorophenyl)acetic acid Chemical compound OC(=O)CC1=CC(Cl)=CC(Cl)=C1 RERINLRFXYGZEE-UHFFFAOYSA-N 0.000 description 1
KYNNBXCGXUOREX-UHFFFAOYSA-N 2-(3-bromophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Br)=C1 KYNNBXCGXUOREX-UHFFFAOYSA-N 0.000 description 1
WFPMUFXQDKMVCO-UHFFFAOYSA-N 2-(3-chlorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=CC(Cl)=C1 WFPMUFXQDKMVCO-UHFFFAOYSA-N 0.000 description 1
MGKPFALCNDRSQD-UHFFFAOYSA-N 2-(4-fluorophenyl)acetic acid Chemical compound OC(=O)CC1=CC=C(F)C=C1 MGKPFALCNDRSQD-UHFFFAOYSA-N 0.000 description 1
DRNNZMMOBSRGPG-UHFFFAOYSA-N 2-(5-oxo-7,8-dihydro-6h-naphthalen-2-yl)acetic acid Chemical compound O=C1CCCC2=CC(CC(=O)O)=CC=C21 DRNNZMMOBSRGPG-UHFFFAOYSA-N 0.000 description 1
YHVGRPXIEKFDRC-IENPIDJESA-N 2-[(2s)-1,4-diiodobutan-2-yl]oxyoxane Chemical compound ICC[C@@H](CI)OC1CCCCO1 YHVGRPXIEKFDRC-IENPIDJESA-N 0.000 description 1
BLXXCCIBGGBDHI-UHFFFAOYSA-N 2-[3-(trifluoromethyl)phenyl]acetic acid Chemical compound OC(=O)CC1=CC=CC(C(F)(F)F)=C1 BLXXCCIBGGBDHI-UHFFFAOYSA-N 0.000 description 1
HNORVZDAANCHAY-UHFFFAOYSA-N 2-[4-(trifluoromethyl)phenyl]acetic acid Chemical compound OC(=O)CC1=CC=C(C(F)(F)F)C=C1 HNORVZDAANCHAY-UHFFFAOYSA-N 0.000 description 1
PBGKTSKYUHBZQM-UHFFFAOYSA-N 2-cyclopenta[b]pyran-2-ylacetic acid Chemical compound O1C(CC(=O)O)=CC=C2C=CC=C21 PBGKTSKYUHBZQM-UHFFFAOYSA-N 0.000 description 1
ARXKVVRQIIOZGF-BYPYZUCNSA-N 2-deoxyerythritol Chemical compound OCC[C@H](O)CO ARXKVVRQIIOZGF-BYPYZUCNSA-N 0.000 description 1
ALKYHXVLJMQRLQ-UHFFFAOYSA-N 3-Hydroxy-2-naphthoate Chemical class C1=CC=C2C=C(O)C(C(=O)O)=CC2=C1 ALKYHXVLJMQRLQ-UHFFFAOYSA-N 0.000 description 1
YNGIFMKMDRDNBQ-UHFFFAOYSA-N 3-ethenylphenol Chemical compound OC1=CC=CC(C=C)=C1 YNGIFMKMDRDNBQ-UHFFFAOYSA-N 0.000 description 1
UPMLOUAZCHDJJD-UHFFFAOYSA-N 4,4'-Diphenylmethane Diisocyanate Chemical compound C1=CC(N=C=O)=CC=C1CC1=CC=C(N=C=O)C=C1 UPMLOUAZCHDJJD-UHFFFAOYSA-N 0.000 description 1
QOWSWEBLNVACCL-UHFFFAOYSA-N 4-Bromophenyl acetate Chemical compound OC(=O)CC1=CC=C(Br)C=C1 QOWSWEBLNVACCL-UHFFFAOYSA-N 0.000 description 1
JLBJTVDPSNHSKJ-UHFFFAOYSA-N 4-Methylstyrene Chemical compound CC1=CC=C(C=C)C=C1 JLBJTVDPSNHSKJ-UHFFFAOYSA-N 0.000 description 1
CDPKJZJVTHSESZ-UHFFFAOYSA-N 4-chlorophenylacetic acid Chemical compound OC(=O)CC1=CC=C(Cl)C=C1 CDPKJZJVTHSESZ-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical class [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 description 1
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
201000004624 Dermatitis Diseases 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
230000005526 G1 to G0 transition Effects 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
239000002841 Lewis acid Substances 0.000 description 1
240000005265 Lupinus mutabilis Species 0.000 description 1
235000008755 Lupinus mutabilis Nutrition 0.000 description 1
240000003183 Manihot esculenta Species 0.000 description 1
235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
102000001490 Opioid Peptides Human genes 0.000 description 1
229940123054 Opioid kappa receptor agonist Drugs 0.000 description 1
108070000021 Opioid peptides receptors Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
208000002193 Pain Diseases 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
235000019095 Sechium edule Nutrition 0.000 description 1
244000000231 Sesamum indicum Species 0.000 description 1
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
244000061456 Solanum tuberosum Species 0.000 description 1
235000002595 Solanum tuberosum Nutrition 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
238000000862 absorption spectrum Methods 0.000 description 1
150000001242 acetic acid derivatives Chemical class 0.000 description 1
239000003377 acid catalyst Substances 0.000 description 1
238000005903 acid hydrolysis reaction Methods 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
125000005042 acyloxymethyl group Chemical group 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
150000001350 alkyl halides Chemical class 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
150000001558 benzoic acid derivatives Chemical class 0.000 description 1
230000027455 binding Effects 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
QRZAKQDHEVVFRX-UHFFFAOYSA-N biphenyl-4-ylacetic acid Chemical compound C1=CC(CC(=O)O)=CC=C1C1=CC=CC=C1 QRZAKQDHEVVFRX-UHFFFAOYSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M bisulphate group Chemical group S([O-])(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
230000037396 body weight Effects 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
229960003563 calcium carbonate Drugs 0.000 description 1
235000010216 calcium carbonate Nutrition 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
239000002775 capsule Substances 0.000 description 1
150000001718 carbodiimides Chemical class 0.000 description 1
238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
QZXCCPZJCKEPSA-UHFFFAOYSA-N chlorfenac Chemical compound OC(=O)CC1=C(Cl)C=CC(Cl)=C1Cl QZXCCPZJCKEPSA-UHFFFAOYSA-N 0.000 description 1
150000001805 chlorine compounds Chemical class 0.000 description 1
150000001860 citric acid derivatives Chemical class 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
235000009508 confectionery Nutrition 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
239000002178 crystalline material Substances 0.000 description 1
238000010511 deprotection reaction Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
150000005690 diesters Chemical class 0.000 description 1
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
JGHYBJVUQGTEEB-UHFFFAOYSA-M dimethylalumanylium;chloride Chemical compound C[Al](C)Cl JGHYBJVUQGTEEB-UHFFFAOYSA-M 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003480 eluent Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
125000004185 ester group Chemical group 0.000 description 1
230000032050 esterification Effects 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
230000006870 function Effects 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
229960002449 glycine Drugs 0.000 description 1
150000008282 halocarbons Chemical class 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
210000000548 hind-foot Anatomy 0.000 description 1
150000003840 hydrochlorides Chemical class 0.000 description 1
238000005984 hydrogenation reaction Methods 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
230000003871 intestinal function Effects 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
102000048260 kappa Opioid Receptors Human genes 0.000 description 1
150000003893 lactate salts Chemical class 0.000 description 1
239000008101 lactose Substances 0.000 description 1
150000007517 lewis acids Chemical class 0.000 description 1
239000003446 ligand Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000006210 lotion Substances 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
159000000003 magnesium salts Chemical class 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
150000002688 maleic acid derivatives Chemical class 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
238000005667 methoxymethylation reaction Methods 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
230000009427 motor defect Effects 0.000 description 1
KXDOGABXVPLQQJ-QFBILLFUSA-N n-[(1s)-1-(4-chlorophenyl)-2-[(3s)-3-hydroxypyrrolidin-1-yl]ethyl]-2-(3,4-dichlorophenyl)-n-hydroxyacetamide Chemical compound C1[C@@H](O)CCN1C[C@H](C=1C=CC(Cl)=CC=1)N(O)C(=O)CC1=CC=C(Cl)C(Cl)=C1 KXDOGABXVPLQQJ-QFBILLFUSA-N 0.000 description 1
150000002823 nitrates Chemical class 0.000 description 1
230000009871 nonspecific binding Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
XYEOALKITRFCJJ-UHFFFAOYSA-N o-benzylhydroxylamine Chemical compound NOCC1=CC=CC=C1 XYEOALKITRFCJJ-UHFFFAOYSA-N 0.000 description 1
HYDZPXNVHXJHBG-UHFFFAOYSA-N o-benzylhydroxylamine;hydron;chloride Chemical compound Cl.NOCC1=CC=CC=C1 HYDZPXNVHXJHBG-UHFFFAOYSA-N 0.000 description 1
239000003399 opiate peptide Substances 0.000 description 1
239000000014 opioid analgesic Substances 0.000 description 1
229940005483 opioid analgesics Drugs 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000003891 oxalate salts Chemical class 0.000 description 1
125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
210000000578 peripheral nerve Anatomy 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000003444 phase transfer catalyst Substances 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
239000006187 pill Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
230000002980 postoperative effect Effects 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000000651 prodrug Substances 0.000 description 1
229940002612 prodrug Drugs 0.000 description 1
ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 description 1
230000006340 racemization Effects 0.000 description 1
150000003254 radicals Chemical class 0.000 description 1
102000005962 receptors Human genes 0.000 description 1
108020003175 receptors Proteins 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
229960001790 sodium citrate Drugs 0.000 description 1
235000011083 sodium citrates Nutrition 0.000 description 1
235000009518 sodium iodide Nutrition 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
235000010265 sodium sulphite Nutrition 0.000 description 1
AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
235000019345 sodium thiosulphate Nutrition 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
239000007921 spray Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
150000003890 succinate salts Chemical class 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000006188 syrup Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
150000003892 tartrate salts Chemical class 0.000 description 1
CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
108020001588 κ-opioid receptors Proteins 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/12—Oxygen or sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Hematology (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Anesthesiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pyrrole Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Furan Compounds (AREA)

SK1298-97A 1995-03-31 1996-03-28 Pyrrolidinyl hydroxamic acid derivatives, method and intermediate products for their production and pharmaceutical compositions process SK129897A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP9500631		1995-03-31
PCT/JP1996/000820 WO1996030339A1 (en)	1995-03-31	1996-03-28	Pyrrolidinyl hydroxamic acid compounds and their production process

Publications (1)

Publication Number	Publication Date
SK129897A3 true SK129897A3 (en)	1998-11-04

Family

ID=14125824

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1298-97A SK129897A3 (en)	1995-03-31	1996-03-28	Pyrrolidinyl hydroxamic acid derivatives, method and intermediate products for their production and pharmaceutical compositions process

Country Status (35)

Country	Link
US (2)	US5952369A (is)
EP (1)	EP0817772B1 (is)
JP (1)	JP3035356B2 (is)
KR (1)	KR100258657B1 (is)
AP (1)	AP625A (is)
AR (1)	AR002729A1 (is)
AT (1)	ATE231840T1 (is)
AU (1)	AU693336B2 (is)
BG (1)	BG62611B1 (is)
BR (1)	BR9607750A (is)
CA (1)	CA2213815C (is)
CZ (1)	CZ306497A3 (is)
DE (1)	DE69626009T2 (is)
DK (1)	DK0817772T3 (is)
ES (1)	ES2188743T3 (is)
HR (1)	HRP960141A2 (is)
HU (1)	HUP9900767A3 (is)
IL (2)	IL117440A0 (is)
IS (1)	IS4547A (is)
LV (1)	LV11971B (is)
MA (1)	MA23832A1 (is)
NO (1)	NO974513L (is)
NZ (1)	NZ304113A (is)
OA (1)	OA10518A (is)
PE (1)	PE43397A1 (is)
PL (1)	PL322652A1 (is)
RU (1)	RU2144917C1 (is)
SI (1)	SI9620039A (is)
SK (1)	SK129897A3 (is)
TN (1)	TNSN96045A1 (is)
TR (1)	TR199701082T1 (is)
TW (1)	TW408111B (is)
WO (1)	WO1996030339A1 (is)
YU (1)	YU18696A (is)
ZA (1)	ZA962476B (is)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX9701042A (es) *	1996-02-07	1998-05-31	Pfizer	Compuestos del acido hidroxamico.
TNSN97092A1 (ar)	1996-09-18	1999-12-31	Agouron Pharma	مثبطات انزيم بروتيني فلزي وتركيبات صيدلانية تحتوي على تلك المثبتطات واستخدامها الصيدلاني وطرق ومركبات وسيطة مفيدة لتحضير التركيبات المذكورة.
WO1998024431A1 (en) *	1996-12-02	1998-06-11	Kyorin Pharmaceutical Co., Ltd.	Novel n-substituted pyrrolidine derivatives and process for preparing the same
CA2276074A1 (en) *	1997-01-10	1998-07-16	Merck & Co., Inc.	Efficient synthesis of a chiral mediator
EP0982297A3 (en) *	1998-08-24	2001-08-01	Pfizer Products Inc.	Process for the preparation of hydroxy-pyrrolidinyl hydroxamic acid derivatives being opioid kappa receptor agonists
KR100295740B1 (ko) *	1998-09-17	2001-11-05	박영구	N-치환된-하이드록시고리화알킬아민유도체의제조방법
US6444829B1 (en) *	2000-07-19	2002-09-03	Hoffmann-La Roche Inc.	Pyrrolidine compounds
JP2005508851A (ja)	2001-04-30	2005-04-07	ファイザー・プロダクツ・インク	カッパーアゴニストとして有用なヒドロキシピロリジニルエチルアミン化合物の調製方法
US7091357B2 (en) *	2001-12-26	2006-08-15	University Of Kentucky Research Foundation	Chain-modified pyridino-N substituted nicotine compounds for use in the treatment of CNS pathologies
GB0202873D0 (en) *	2002-02-07	2002-03-27	Novartis Ag	Organic compounds
AU2003269399A1 (en) *	2002-11-01	2004-05-25	Pfizer Products Inc.	Process for the preparation of pyrrolidinyl ethylamine compounds via a copper-mediated aryl amination
EP1615883A1 (en) *	2003-04-14	2006-01-18	Warner-Lambert Company	Process for preparing 5-(4-fluorophenyl)-1-[2-((2r,4r)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1h-pyrrole-3-carboxylic acid phenylamide
UA89035C2 (ru) *	2003-12-03	2009-12-25	Лео Фарма А/С	Эфиры гидроксамовых кислот и их фармацевтическое применение
GB0821010D0 (en) *	2008-11-17	2008-12-24	Univ Warwick	Plant development control composition
JP6254075B2 (ja)	2011-05-16	2017-12-27	バイオノミックスリミテッド	カリウムチャネル遮断剤としてのアミン誘導体
KR101773331B1 (ko) *	2012-03-05	2017-08-31	닥터 레디스 레보러터리즈 리미티드	카파 오피오이드 수용체(κor) 작용제인 치환된 헤테로시클릭 아세트아미드
GB201210395D0 (en) *	2012-06-11	2012-07-25	Syngenta Participations Ag	Crop enhancement compositions

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3268539A (en) *	1963-05-20	1966-08-23	Universal Oil Prod Co	Tertiary-aminoalkyl derivatives of diaryl substituted acetohydroxamic acid esters

1996
- 1996-03-11 IL IL11744096A patent/IL117440A0/xx unknown
- 1996-03-14 AP APAP/P/1996/000791A patent/AP625A/en active
- 1996-03-15 TW TW085103136A patent/TW408111B/zh active
- 1996-03-25 PE PE1996000208A patent/PE43397A1/es not_active Application Discontinuation
- 1996-03-25 MA MA24191A patent/MA23832A1/fr unknown
- 1996-03-26 HR HRPCT/JP95/631A patent/HRP960141A2/hr not_active Application Discontinuation
- 1996-03-27 YU YU18696A patent/YU18696A/sh unknown
- 1996-03-28 SK SK1298-97A patent/SK129897A3/sk unknown
- 1996-03-28 DE DE69626009T patent/DE69626009T2/de not_active Expired - Fee Related
- 1996-03-28 CA CA002213815A patent/CA2213815C/en not_active Expired - Fee Related
- 1996-03-28 AT AT96907686T patent/ATE231840T1/de not_active IP Right Cessation
- 1996-03-28 RU RU97117590A patent/RU2144917C1/ru active
- 1996-03-28 JP JP08529174A patent/JP3035356B2/ja not_active Expired - Fee Related
- 1996-03-28 ZA ZA9602476A patent/ZA962476B/xx unknown
- 1996-03-28 PL PL96322652A patent/PL322652A1/xx unknown
- 1996-03-28 ES ES96907686T patent/ES2188743T3/es not_active Expired - Lifetime
- 1996-03-28 AU AU51211/96A patent/AU693336B2/en not_active Ceased
- 1996-03-28 TR TR97/01082T patent/TR199701082T1/xx unknown
- 1996-03-28 KR KR1019970706880A patent/KR100258657B1/ko not_active Expired - Fee Related
- 1996-03-28 DK DK96907686T patent/DK0817772T3/da active
- 1996-03-28 EP EP96907686A patent/EP0817772B1/en not_active Expired - Lifetime
- 1996-03-28 BR BR9607750A patent/BR9607750A/pt active Search and Examination
- 1996-03-28 SI SI9620039A patent/SI9620039A/sl not_active IP Right Cessation
- 1996-03-28 HU HU9900767A patent/HUP9900767A3/hu unknown
- 1996-03-28 CZ CZ973064A patent/CZ306497A3/cs unknown
- 1996-03-28 NZ NZ304113A patent/NZ304113A/xx unknown
- 1996-03-28 US US08/913,823 patent/US5952369A/en not_active Expired - Fee Related
- 1996-03-28 WO PCT/JP1996/000820 patent/WO1996030339A1/en not_active Ceased
- 1996-03-29 TN TNTNSN96045A patent/TNSN96045A1/fr unknown
- 1996-03-29 AR ARP960101993A patent/AR002729A1/es unknown
1997
- 1997-08-19 IS IS4547A patent/IS4547A/is unknown
- 1997-09-17 BG BG101896A patent/BG62611B1/bg unknown
- 1997-09-29 NO NO974513A patent/NO974513L/no not_active Application Discontinuation
- 1997-09-30 OA OA70091A patent/OA10518A/en unknown
- 1997-10-21 LV LVP-97-203A patent/LV11971B/en unknown
1999
- 1999-04-15 IL IL12947999A patent/IL129479A0/xx unknown
- 1999-04-29 US US09/302,097 patent/US6110947A/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CA2213815A1 (en)	1996-10-03
US6110947A (en)	2000-08-29
KR100258657B1 (ko)	2000-07-01
AU693336B2 (en)	1998-06-25
ES2188743T3 (es)	2003-07-01
BR9607750A (pt)	1998-06-30
PE43397A1 (es)	1997-10-13
IL129479A0 (en)	2000-02-29
LV11971A (lv)	1998-02-20
KR19980703476A (ko)	1998-11-05
AR002729A1 (es)	1998-04-29
BG62611B1 (bg)	2000-03-31
ATE231840T1 (de)	2003-02-15
EP0817772A1 (en)	1998-01-14
PL322652A1 (en)	1998-02-16
HUP9900767A2 (hu)	1999-07-28
AP9600791A0 (en)	1996-04-30
EP0817772B1 (en)	2003-01-29
ZA962476B (en)	1997-09-29
TNSN96045A1 (fr)	2005-03-15
WO1996030339A1 (en)	1996-10-03
DK0817772T3 (da)	2003-05-19
CZ306497A3 (cs)	1998-07-15
YU18696A (sh)	1999-06-15
IS4547A (is)	1997-08-19
IL117440A0 (en)	1996-07-23
OA10518A (en)	2002-04-22
HUP9900767A3 (en)	2001-01-29
DE69626009T2 (de)	2003-08-14
BG101896A (en)	1999-01-29
JP3035356B2 (ja)	2000-04-24
MA23832A1 (fr)	1996-10-01
AP625A (en)	1997-12-24
NO974513D0 (no)	1997-09-29
SI9620039A (sl)	1998-08-31
HRP960141A2 (en)	1997-10-31
LV11971B (en)	1998-06-20
JPH11501048A (ja)	1999-01-26
DE69626009D1 (de)	2003-03-06
MX9707454A (es)	1998-07-31
TW408111B (en)	2000-10-11
CA2213815C (en)	2001-12-18
TR199701082T1 (xx)	1998-02-21
NO974513L (no)	1997-09-29
NZ304113A (en)	1999-01-28
US5952369A (en)	1999-09-14
RU2144917C1 (ru)	2000-01-27
AU5121196A (en)	1996-10-16

Publication	Publication Date	Title
SK129897A3 (en)	1998-11-04	Pyrrolidinyl hydroxamic acid derivatives, method and intermediate products for their production and pharmaceutical compositions process
RU2125041C1 (ru)	1999-01-20	Арилацетамиды, способ их получения, фармацевтическая композиция и способ ее получения
SK278434B6 (en)	1997-05-07	3-substituted pyrolidine derivative, preparation method thereof, intermediate products of this method, pharmaceutical composition containing this derivative
EP0629190A1 (en)	1994-12-21	Compounds as calcium channel antagonists
US6294557B1 (en)	2001-09-25	Pyrrolidinyl and pyrrolinyl ethylamine compounds as kappa agonists
WO1992022527A2 (en)	1992-12-23	3-substituted pyrrolidine derivatives as calcium channel antagonists
JP2935899B2 (ja)	1999-08-16	▲下ｋ▼レセプターアゴニストとしてのｎ−（２−（ピロリジニル−１）−１−フェニルエチル）アセトアミド
GB2068373A (en)	1981-08-12	Cyclohexene derivatives
Liu et al.	2017	Divergent syntheses of L-733, 060 and CP-122721 from functionalized pieridinones made by one-pot tandem cyclization
Hussaini et al.	2006	2, 5-Disubstituted pyrrolidines: synthesis by enamine reduction and subsequent regioselective and diastereoselective alkylations
US5387688A (en)	1995-02-07	Intermediates for making analgesic N-phenyl-N-(3-OR1 -3-Me-4-piperidinyl)amides
JP3245578B2 (ja)	2002-01-15	ピロリジニルヒドロキサム酸化合物の製造方法
NZ233002A (en)	1992-07-28	3-(aminoalkyl)benzothiopyran derivatives and pharmaceutical compositions
EP0789021B1 (en)	2000-10-11	Hydroxamic acid compounds as opioid kappa receptor agonists
US5716936A (en)	1998-02-10	Pyrrolidine derivatives for the treatment of cholecystokinine and gastrine-related disorders
MXPA97007454A (en)	1998-11-09	Hydroxamic pirrolidinil acid compounds and their product procedure
US5130321A (en)	1992-07-14	Analgesic n-phenyl-n-(3-or 1-3-me-4-piperidinyl)amides
EP1461317A2 (en)	2004-09-29	Process for preparing hydroxypyrrolidinyl ethylamine compounds useful as kappa agonists
PT789021E (pt)	2001-02-28	Compostos de acido pirrolidinil hidroxamico e o processo para a sua producao
CZ9902390A3 (cs)	2000-10-11	Způsob výroby derivátů pyrrolidinylhydroxamové kyseliny